Moderna’s stock climbed 838.4% during the pandemic but has dropped 34% this year. Despite revenue falling to $142 million and a net loss of $825 million, the company has $7.5 billion in reserves and cut operational expenses by 40%. Three FDA approvals signal progress in stabilizing the vaccine portfolio.

Moderna is investing in a diverse mRNA portfolio, including flu vaccines and oncology programs with Merck. The company aims to lower operational expenses from $11 billion in 2023 to $5 billion by 2027. Despite revenue guidance adjustments, Moderna plans to have around $6 billion in cash and investments by year-end.

Moderna is transitioning to a leaner, more disciplined company with a strong pipeline. Although facing challenges in the post-pandemic market, long-term investors may consider buying or holding stock. Wall Street analysts rate the stock a “Hold,” with a target price of $42.50, suggesting a potential 56% rally and a high estimate of 627% growth over the next 12 months.

Read more at Yahoo Finance: Moderna Stock Is at a Crossroads. Is the Path Ahead One of Profit or Pain for MRNA?